Director General of the Indian Council of Medical Research (ICMR), Dr Balram Bhargava said three vaccine candidates are at different clinical trial stages in India. Covid-19 vaccine candidates being manufactured by Cadila Healthcare and Bharat Biotech have completed the first phase of the trial while the Serum Institute of India (SII) will begin with Phase 3 trial after getting the nod, Balram Bhargava, ICMR’s director general, said during the health ministry’s briefing.The Pune-based Serum Institute will conduct the Phase 3 trial on 1,500 volunteers across 14 locations, Bhargava added.
Credit: HT Digital Content Duration: 01:19Published
Indian Council of Medical Research, Director General Dr. Balram Bhargava during Health Ministry's briefing on COVID-19 situation in India informed about the sero survey publication. Bhargava said, "ICMR sero survey is publication in-progress. It should appear by this week in the Indian Journal of Medical Research. It has been peer reviewed. The second national sero-survey should be completed in the first week September". On situation of COVID-19 vaccines in India, Balram Bhargava said, "Three COVID-19 vaccines are ahead in the race in India. Serum Institute's vaccine is in phase 2(B) and phase 3 trials and Bharat Biotech and Zydus Cadila's vaccines have completed phase 1 trial."
Nicola Sturgeon said the R number in Scotland – the average number of otherpeople infected with the virus by each person with Covid-19 – could nowpossibly be as high as 1.6. Speaking at the start of First Minister’sQuestions at Holyrood, she said the latest figures showed why the ScottishGovernment had announced further “tough measures” aimed at curbingcoronavirus.
Credit: PA - Press Association STUDIO Duration: 01:30Published
India's COVID-19 tally crossed 56-lakh mark on September 23 with a spike of 83,347 new infections. Total COVID-19 cases in the country stand at 56,46,011. Currently, there are 9,68,377 active cases. With 1,085 deaths in last 24 hours, the death toll rises to 90,020. Indian Council of Medical Research reported that 6,62,79,462 samples were tested up to September 22. Further, the Health Ministry informed that India's COVID-19 testing capacity surges to over 12 lakh daily tests.
India's COVID tally crossed 55-lakh mark on September 22 after the country reported a spike of 75,083 new COVID-19 cases. Total COVID case tally stands at 55, 62,664, including 9,75,861 active cases, 44,97,868 discharged. With 1,053 deaths in the last 24 hours, death toll due to COVID reached 88,935. Indian Council of Medical Research reported that 6,53,25,779 samples were tested up to September 21 for the virus. Of these, 9,33,185 samples were tested on September 21.
From another minister in the Narendra Modi cabinet testing positive for infection, to the progress report of India's indigenously-developed vaccine candidates - here are the top news updates on the Covid-19 pandemic. Union minister of petroleum and natural gas, and steel, Dharmendra Pradhan, tested positive days after Union Home minister Amit Shah confirmed his positive diagnosis. Meanwhile, other members of the Union cabinet, like Ravi Shankar Prasad and Babul Supriyo, are quarantining themselves as a precaution. On the medical front, India's two vaccine candidates have completed phase 1 of human clinical trials. The vaccines have been developed by Bharat Biotech, ICMR and Zydus Cadila. The Jammu and Kashmir administration has decided to allow all places of worship to reopen from August 16. Earlier, the authorities had decided to cancel the annual Amarnath Yatra due to the Covid pandemic. In economic news, the International Monetary Fund has said that Covid might exacerbate the narrowing of global current account imbalances which was happening due to trade slowdown in 2019. Watch the full video for the other updates on the spread of the Sars-CoV-2 coronavirus.
Credit: HT Digital Content Duration: 02:41Published
Post Graduate Institute (PGI) Rohtak will start the phase-2 human clinical trial of Bharat Biotech's COVID-19 vaccine. “We got permission from Bharat Biotech to start a phase-2 human clinical trial of their vaccine. We've 300 volunteers, aged between 12 years and 65- years, out of which screening of 15 has been completed,” said Dr OP Kalra, vice-chancellor, PGI Rohtak. Kalra also informed that in the phase-2 trail, they have recruited volunteers who have controlled diabetes and high blood pressure. Watch the full video for more details.
Credit: HT Digital Content Duration: 01:48Published